GlassScriptPhysician profile
Samah Nassereddine
NPI 1235552290
$10,515.22
in general payments reported to CMS, 2019-2025
28 companies · $438 in 2025
The $438 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $16.57 · 2021: $184 · 2022: $6,033 · 2023: $2,886 · 2024: $207 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,475 · Food and Beverage: $1,004 · Travel and Lodging: $52.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,475.00 |
| Food and Beverage | $1,004.12 |
| Travel and Lodging | $52.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $5,830.92 | 2022 | |
| Abbvie INC. | $2,652.43 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $241.34 | 2019-2021 | |
| Celgene Corporation | $219.41 | 2019-2025 | Reblozyl |
| Incyte Corporation | $202.83 | 2019-2024 | Jakafi |
| Janssen Biotech, INC. | $129.84 | 2024-2025 | Tecvayli, Erleada, Carvykti |
| Pharmaessentia USA Corporation | $124.99 | 2023 | Besremi |
| Geron Corporation | $115.70 | 2025 | Rytelo |
| E.R. Squibb & Sons, L.L.C. | $112.63 | 2022 | |
| Beigene USA, INC. | $108.82 | 2023 | Brukinsa |
| Adaptive Biotechnologies Corporation | $104.99 | 2019 | |
| Amgen INC. | $99.99 | 2019 | |
| Astellas Pharma US INC | $95.00 | 2019 | |
| Rigel Pharmaceuticals, INC. | $84.91 | 2019 | |
| Pfizer INC. | $67.20 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35.15 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $32.22 | 2022 | |
| Merck Sharp & Dohme LLC | $31.65 | 2025 | Keytruda, Keytruda Qlex |
| Exelixis INC. | $31.11 | 2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $28.61 | 2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $24.98 | 2021 | |
| Caris Mpi, INC. | $22.02 | 2025 | Mi Cancer Seek |
| Myriad Genetic Laboratories, INC. | $21.22 | 2024 | Myrisk |
| Ipsen Biopharmaceuticals, INC | $20.78 | 2024 | Somatuline Depot, Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $20.37 | 2025 | |
| Pharmacosmos Therapeutics INC. | $20.08 | 2024 | Cosela |
| Genmab U.S., INC. | $19.86 | 2025 | Epkinly |
| Daiichi Sankyo INC. | $16.17 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samah Nassereddine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.